Rexall names Warren Jeffery COO
MISSISSAUGA, Ontario — Industry veteran Warren Jeffery has been appointed Rexall’s COO. Jeffery is rejoining the company after retiring in 2011.
In his new role, Jeffery will lead store operations, merchandising, real estate and acquisitions with the objective of accelerating the company’s growth.
“Rexall’s strategy has never been more compelling, and our customers are responding favorably to our new brand positioning. Warren, a registered pharmacist, brings tremendous retail experience and a proven track record of success in growing retail pharmacy businesses. Warren’s experience gives me great confidence in his ability to accelerate Rexall’s growth and help the organization navigate through new government reforms that continue to expand community pharmacists’ scope of practice,” said Frank Scorpiniti, CEO of Rexall.
Albany pharmacy dean looking for industry input
Albany, N.Y. — The new dean of the Albany College of Pharmacy and Health Sciences, Gregory Dewey, is looking to gain insight from industry experts.
Dewey, who was appointed dean in June, told the Albany Business Review that he would put together a corporate board to get an idea of what skills industry leaders look for from graduates, and what skills they might be missing.
"It's a time of changing roles in the healthcare profession, and we want to be advancing our students to meet some of these changing roles," Dewey said.
Already, pharmaceutical and pharmacy insiders from New York and New Englad have expressed interest in being on the board, including Kinney Drugs and Albany Molecular Research. The first meeting will be in October.
FDA approves Jardiance tabs
SILVER SPRING, Md. — The Food and Drug Administration announced approval for Jardiance (empagliflozin) tablets, which is to be used as an addition to diet and exercise to improve glycemic control in adults with Type 2 diabetes.
The drug is a sodium glucose co-transporter 2 (SGLT2) inhibitor. It works by blocking the reabsorption of glucose by the kidney, increasing glucose excretion, and lowering blood glucose levels in diabetics who have elevated blood glucose levels, the agency stated.
"Jardiance provides an additional treatment option for the care of patients with type 2 diabetes," said Curtis J. Rosebraugh, M.D., M.P.H., director of the Office of Drug Evaluation II in the FDA’s Center for Drug Evaluation and Research. “It can be used alone or added to existing treatment regimens to control blood sugar levels in the overall management of diabetes.”
Jardiance is distributed by Boehringer Ingelheim Pharmaceuticals.